

## Development of ALCAM aptamer-based ApDC anticancer drug



ONCOLOGY	Hit
Product Type	HC 102D : ApDC (Aptamer Drug Conjugation)
Indication	Metastatic cancer (metastatic ovarian cancer)
Target	Tumor-specific ALCAM protein
MoA(Mechanism of Action)	Dual anti-cancer effect (tumor-selective drug delivery, inhibition of FAK signaling in the tumor microenvironment)
Competitiveness	<ul style="list-style-type: none"> <li>• Tumor-specific binding: Tumor-selective binding according to the presence of N-glycoprotein present only in tumor ALCAM protein</li> <li>• Anti-cancer synergy effect: This technology can cause drug therapy and signal transduction inhibition at the same time with one treatment</li> <li>• Utilization of drug delivery platform: Utilization as a new delivery platform for various drugs that have been withdrawn due to difficulties in targeting</li> <li>• Various routes of administration: Since aptamers do not show immunogenicity, they can be administered intraperitoneally, unlike antibodies or CAR-T therapeutics.</li> <li>• First-In-Class: Ovarian cancer (metastatic cancer) treatment using aptamer is a first-in-class new drug, and its unrivaled market position is guaranteedPossible to secure exclusive rights: It is possible to secure exclusive beta rights for a long period of time with new products.</li> </ul>
Development Stage	Hit
Route of Administration	I.V (Intravenous) / I.P(intraperitoneal) injection